4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Veraxa Biotech AG (VRXA) operates in the Biotechnology industry and is headquartered in Heidelberg, Germany. Its market capitalization is roughly $351 million. In the fiscal year ended 2025-12-31, VRXA reported $0M in revenue and ($67M) in net income.
VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment.
Interactive charts & full statements →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Revenue | $0M | $0M | $0M |
| Gross Profit | $0M | $0M | — |
| Operating Income (EBIT) | ($66M) | ($29M) | ($17M) |
| Net Income | ($67M) | ($28M) | ($16M) |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total Assets | $81M | $85M | $92M |
| Total Liabilities | $97M | $54M | $37M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive VRXA viewer.
About TickerBase · Data methodology & sources